Wall Street Zen Upgrades Immunic (NASDAQ:IMUX) to Hold

Key Points

• Wall Street Zen upgraded Immunic (NASDAQ:IMUX) from a "sell" to a "hold" in a research note issued Saturday.
• Analyst coverage is mixed but tilted positive — two "strong buy," six "buy" and one "sell" — with an overall average rating of "Buy" and an average price target of $6.17 (Guggenheim initiated coverage at $7.00 while others have cut targets to as low as $4.00–$5.00).
• Immunic shares opened at $1.17 with a market cap of $152.6M, reported negative EPS last quarter (‑$0.12) and are forecast to post about ‑0.94 EPS for the year, while institutional investors own roughly 51.8% of the stock.

Immunic (NASDAQ:IMUX - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

A number of other research analysts have also commented on IMUX. Guggenheim initiated coverage on Immunic in a report on Tuesday, March 24th. They set a "buy" rating and a $7.00 price target on the stock. D. Boral Capital lowered their price objective on shares of Immunic from $8.00 to $4.00 and set a "buy" rating on the stock in a research note on Friday, February 13th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Immunic in a research note on Monday, December 29th. HC Wainwright lowered their price objective on shares of Immunic from $8.00 to $5.00 and set a "buy" rating on the stock in a research note on Monday, March 2nd. Finally, upgraded shares of Immunic to a "strong-buy" rating in a research note on Tuesday, February 3rd. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $6.17.

Immunic Stock Performance

Shares of IMUX opened at $1.17 on Friday. The firm has a market capitalization of $152.64 million, a price-to-earnings ratio of -1.67 and a beta of 1.37. Immunic has a one year low of $0.51 and a one year high of $1.51. The stock's fifty day moving average is $1.04 and its 200-day moving average is $0.83.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.02). Analysts forecast that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Qube Research & Technologies Ltd acquired a new position in Immunic during the third quarter worth about $29,000. Two Sigma Investments LP acquired a new position in Immunic in the third quarter worth approximately $52,000. HB Wealth Management LLC acquired a new position in Immunic in the third quarter worth approximately $81,000. Virtu Financial LLC bought a new position in shares of Immunic in the third quarter valued at $99,000. Finally, Seven Fleet Capital Management LP bought a new position in shares of Immunic in the fourth quarter valued at $83,000. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.